Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHK-336 in Healthy Volunteers
NCT05367661Phase 1Terminated
- Sponsor
- Chinook Therapeutics
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CHK-336 in Primary hyperoxaluria (PH), hyperoxaluria and nephrolithiasis (4 arms), sponsored by Chinook Therapeutics. Primary endpoint: Safety and tolerability of single ascending doses and multiple ascending doses up to 28 days. Started Apr 2022; status: terminated.
02
Drugs
CHK-336
03
Conditions
Primary hyperoxaluria (PH)hyperoxalurianephrolithiasis
Beyond the preview
Go deeper on NCT05367661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367661.